Press Release
Source: Viral Genetics, Inc.

Beacon Equity Issues Technical Trading Overview for Viral Genetics Inc.

DALLAS, Aug. 31, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring Viral Genetics Inc. (Pink Sheets:VRAL). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

The investment report on Viral Genetics Inc. (Pink Sheets:VRAL) should be of particular interest to other pharmaceutical companies: Gilead Sciences Inc. (Nasdaq:GILD), GlaxoSmithKline plc (NYSE:GSK) and Bristol-Myers Squibb Co. (NYSE:BMY).

It is available at: http://www.beaconequity.com/i/VRAL

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity

Viral Genetics Inc. (VRAL) engages in the development of immune-based therapies for the treatment of HIV/AIDS. The Company's thymus nuclear protein compound has a potential to treat other diseases, such as autoimmune and immunological deficiencies.

In the report, the analyst notes:

"The market for the treatment of HIV/AIDS is rapidly changing, with $8 billion presently spent on drug therapies associated with the disease. Due to the mutation of the virus, the market leadership is changing. GlaxoSmithKline leads in the HIV/AIDS market, but is expected to succumb to research and development of other treatments by competitors as the virus mutates. According to analyst Mansi Shah of research firm Datamonitor, it's anticipated the market will increase by 50% by 2016, with two-thirds of HIV patents expiring during the next decade.

"On August 7, the Company announced it has formed a wholly owned subsidiary, MetaCytoLytics, to develop Metabolic Disruption Technology (MDT) to treat tumor cells by arresting glucose and other fatty acids from providing energy to the cancer cells. The technology has demonstrated its efficacy to directly cause cancer cells to die in animals. Synergizing techniques with other radiation therapies are also indicated in the study."

To read the entire report visit: http://www.beaconequity.com/i/VRAL

See what investors are saying about these stocks at: http://www.stockhideout.com/

BeaconEquity.com is one of the industry's largest small-cap report and small-cap research providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com

Beacon Equity Disclosure

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

CONTACT: Beacon Equity Research
Jeff Bishop
(469)-252-3505
press@beaconequity.com

About Viral Genetics

Viral Genetics, Inc. is a biotechnology company that discovers and develops immune-based therapies for HIV and AIDS using its thymus nuclear protein compound (TNP). The company recently entered into an Exclusive License Agreement with the University of Colorado and V-Clip Pharmaceuticals (a subsidiary of the Company) to license technology developed by M. Karen Newell, PhD that appears to explain TNP and provide a means to optimize therapies based on TNP for future clinical trials. TNP may have other potential applications for other infectious, autoimmune, and immunological deficiency diseases that the company intends to study in the future. Viral Genetics believes that its investigational HIV/AIDS drug based on TNP, called VGV-1, represents a unique approach to treating HIV due to the apparently novel mechanism, low toxicity profile, simple dosing regimen, and short-course of treatment. As a type of immune-based therapy, it focuses on boosting the immune system to allow the body to fight HIV more efficiently. VGV-1 has been studied in five human clinical trials for the treatment of HIV/AIDS. Online at www.viralgenetics.com.

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports filed with the SEC. VGV-1 is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Viral Genetics believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of VGV-1 in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of VGV-1 in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.

Contact:
Viral Genetics
Haig Keledjian, 626-334-5310

Click here to return to our Press Release selection page.

Press Releases

Media Kits

Media Inquiries

News Subscription Service